<DOC>
	<DOCNO>NCT02693171</DOCNO>
	<brief_summary>The purpose study assess incidence human anti-chimeric antibody ( HACA ) high-risk neuroblastoma patient treat Unituxin combination therapy .</brief_summary>
	<brief_title>Post-Marketing Assessment Immunogenicity Safety Unituxinâ„¢ High-Risk Neuroblastoma Patients</brief_title>
	<detailed_description>This multi-center , non-randomized , open-label study patient high-risk neuroblastoma ass immunogenicity , safety tolerability Unituxin combination therapy . Patients enrol study prescribe Unituxin treatment high-risk neuroblastoma .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient diagnose highrisk neuroblastoma . Patient prescribe Unituxin plan start Unituxin therapy within 30 day study entry . Patient must start Unituxin therapy later 200 day Autologous Stem Cell Transplantation ( ASCT ) . Written inform consent / assent must obtain accordance institutional ICH guideline . Patient receive prior antiGD2 antibody therapy . Patient participate investigational clinical trial tumor therapeutic intent within 30 day inform consent . Patient underwent Autologous Stem Cell Transplantation ( ASCT ) 200 day prior receive Unituxin therapy .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>